145 related articles for article (PubMed ID: 26973048)
1. Exploring isoxazole and carboxamide derivatives as potential non-nucleoside reverse transcriptase inhibitors.
Kurup SS; Joshi KA
J Mol Graph Model; 2016 Apr; 65():113-28. PubMed ID: 26973048
[TBL] [Abstract][Full Text] [Related]
2. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket.
Chen X; Meng Q; Qiu L; Zhan P; Liu H; De Clercq E; Pannecouque C; Liu X
Chem Biol Drug Des; 2015 Jul; 86(1):122-8. PubMed ID: 25358434
[TBL] [Abstract][Full Text] [Related]
4. Identification of Adjacent NNRTI Binding Pocket in Multi-mutated HIV1- RT Enzyme Model: An in silico Study.
Kamil RF; Debnath U; Verma S; Prabhakar YS
Curr HIV Res; 2018; 16(2):121-129. PubMed ID: 29651941
[TBL] [Abstract][Full Text] [Related]
5. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
6. An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones.
Massarotti A; Coluccia A
J Mol Graph Model; 2016 Jan; 63():49-56. PubMed ID: 26650686
[TBL] [Abstract][Full Text] [Related]
7. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads.
Vadivelan S; Deeksha TN; Arun S; Machiraju PK; Gundla R; Sinha BN; Jagarlapudi SA
Eur J Med Chem; 2011 Mar; 46(3):851-9. PubMed ID: 21272964
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
10. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
Cele FN; Ramesh M; Soliman ME
Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1.
Singh A; Yadav D; Yadav M; Dhamanage A; Kulkarni S; Singh RK
Chem Biol Drug Des; 2015 Mar; 85(3):336-47. PubMed ID: 25055732
[TBL] [Abstract][Full Text] [Related]
12. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
13. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
14. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
15. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.
Shen L; Shen J; Luo X; Cheng F; Xu Y; Chen K; Arnold E; Ding J; Jiang H
Biophys J; 2003 Jun; 84(6):3547-63. PubMed ID: 12770866
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
17. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
García-Sosa AT; Sild S; Takkis K; Maran U
J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
[TBL] [Abstract][Full Text] [Related]
18. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments.
Brandt P; Geitmann M; Danielson UH
J Med Chem; 2011 Feb; 54(3):709-18. PubMed ID: 21207958
[TBL] [Abstract][Full Text] [Related]
19. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
[TBL] [Abstract][Full Text] [Related]
20. Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors-In Silico Activity Prediction.
Dąbrowska A; Pieńko T; Taciak P; Wiktorska K; Chilmonczyk Z; Mazurek AP; Stasiulewicz A
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
